Novartis' Rhapsido Clears Two MS Trials on Relapse Rates
Novartis' Rhapsido, an approved chronic itch pill, hit its mark in two identical Phase 3 multiple sclerosis trials, cutting annualized relapse rates with a safety profile that looks cleaner than rival BTK…
Novartis said its BTK inhibitor Rhapsido, currently approved as a chronic itch treatment, significantly cut annualized relapse rates in two identically designed Phase 3 multiple sclerosis trials, with safety data the company says compares favorably with rival BTK inhibitors.
Novartis has a second life planned for a pill it already sells for chronic itch. The company said its Bruton's tyrosine kinase inhibitor Rhapsido significantly reduced annualized relapse rates in two identically designed Phase 3 trials in multiple sclerosis, and that the safety data look better than what rival drugs in the same class have produced.
That combination — efficacy on the standard relapse endpoint plus a clean liver signal — is exactly what the BTK field in MS has been missing. Reporting on the readout, Endpoints News framed the result as a credible path for Rhapsido out of dermatology and into one of neurology's largest commercial markets.
What annualized relapse rate actually measures
Annualized relapse rate, or ARR, is the workhorse endpoint of relapsing MS trials: the average number of confirmed neurological flare-ups a patient suffers per year on treatment. Regulators have accepted it for decades because relapses are countable, adjudicable and directly tied to how patients experience the disease. A statistically significant cut in ARR is the entry ticket to an MS label.
Novartis ran two trials rather than one, built to the same protocol. That matters more than it sounds. Replication across identical studies removes the argument that a single result was a fluke of site mix or patient population, and it is the structure the FDA and the European Medicines Agency most like to see when a sponsor is moving a molecule into a new indication. Two consistent wins also strengthen the company's hand in pricing conversations with payers, who are quick to discount a lone positive study.
The company has not, in this readout, put Rhapsido forward as more effective than existing MS therapies. The claim being made is narrower and, commercially, possibly more useful: comparable relapse control with a safety profile that avoids the problem that has dogged the class.
Why the safety line is the whole story for BTK drugs
BTK inhibitors were supposed to be the next structural advance in MS. They are small molecules — pills, not infusions — and they act on B cells and on microglia inside the central nervous system, which is where the slow, non-relapsing progression of the disease is thought to be driven. Existing high-efficacy MS drugs are largely antibodies that do not cross into the brain, and they are administered in a clinic.
The class has repeatedly stumbled on liver toxicity. Elevated transaminases and cases of drug-induced liver injury have forced dose holds, trial pauses and restrictive monitoring language on competing BTK programs, and any of those outcomes turns a convenience-first oral therapy into something a neurologist has to think twice about prescribing. Chronic disease, decades of dosing, mostly younger patients: the tolerance for a tolerability problem is close to zero.
Rhapsido reaches this point with an advantage that none of its BTK rivals had at the equivalent stage — it is already an approved drug, with a real-world safety record in chronic itch patients. Regulators reviewing a supplemental indication get to look at post-marketing data rather than a first-in-class safety database assembled entirely from trials.
The commercial arithmetic behind an MS label
Multiple sclerosis is one of the highest-value chronic disease markets in specialty pharma, dominated by high-priced, high-efficacy antibodies and a long tail of older oral agents that are cheaper and less potent. What has never existed is an oral therapy with antibody-grade relapse control and untroubled tolerability. That is the gap Novartis is aiming at.
What has never existed is an oral therapy with antibody-grade relapse control and untroubled tolerability.
Novartis also already knows this market. The company sells an established oral MS franchise and an injectable B-cell agent, meaning it has a neurology sales organization, prescriber relationships and payer contracts in place. Adding an indication to a marketed pill is among the cheapest expansions available in drug development — no new manufacturing, no new commercial buildout, and a shorter regulatory route than a novel molecule.
The offsetting risk is internal competition. Any MS launch that succeeds will pull some volume from Novartis' own portfolio, and the company will have to decide which patient segments Rhapsido is positioned for: newly diagnosed patients who want to stay on pills, or patients cycling off high-efficacy infusions.
How the shares are positioned into the readout
Novartis (NVS) last closed at 152.06, down 1.14% on the session, having traded between 151.69 and 152.14 low-to-high in a range of 151.69 to 152.74 against a prior close of 153.81, as of the last trade on Aug. 31, 2026 at 20:00 GMT. The broad market was soft the same day: the S&P 500 proxy SPY closed at $767.05, off 0.30%, the Dow tracker DIA at $531.57, down 0.65%, while the Nasdaq 100 fund QQQ edged up 0.05% to $716.76.
For a company of Novartis' size, a single indication expansion rarely moves the stock in one session. The value shows up over quarters, in prescription trends and in whether the safety differentiation survives contact with a full label. Investors watching this one should be less interested in the day's tape than in three specific things.
What to watch next
- The full dataset. Topline statements about ARR and safety are not the same as presented hepatic enzyme data, discontinuation rates and disability-progression measures. The detail will arrive at a medical meeting or in a peer-reviewed journal.
- Regulatory filings. Whether Novartis submits in both the US and Europe, and how quickly, signals how confident it is in the safety package.
- Label language. If Rhapsido's MS label carries lighter liver-monitoring requirements than competing BTK drugs, the safety claim becomes a marketable fact rather than a comparison across trials.
- Disability progression. Relapse reduction sells the drug to payers; slowing progression is what the class was built to do, and the eventual data there will determine whether BTK inhibitors reshape MS treatment or simply add another oral option.
For now, Novartis has done the hard part twice over. In a class defined by what went wrong, arriving with two matching wins and no liver headline is its own kind of differentiation.
Key facts
- Drug: Rhapsido, a BTK inhibitor currently approved for chronic itch
- Trial result: Two identically designed Phase 3 MS trials significantly cut annualized relapse rates
- Differentiator: Safety data suggest an advantage over rival BTK inhibitors
- NVS last close: 152.06, -1.14%, as of Aug. 31, 2026, 20:00 GMT
Frequently asked questions
What is Rhapsido and how does it work?
Rhapsido is Novartis' Bruton's tyrosine kinase (BTK) inhibitor, an oral small molecule currently approved as a treatment for chronic itch. BTK inhibitors act on B cells and on immune cells inside the central nervous system, which is why the class has been pursued in multiple sclerosis, where B-cell activity drives relapses and inflammation.
What did the Phase 3 multiple sclerosis trials show?
Novartis reported that Rhapsido significantly reduced annualized relapse rates in two identically designed Phase 3 trials in multiple sclerosis. The company also indicated the safety data compare favorably with competing BTK inhibitors. Full numerical results, including liver enzyme and disability-progression measures, have not been detailed in the topline announcement.
Why does annualized relapse rate matter?
Annualized relapse rate, or ARR, is the average number of confirmed MS flare-ups a patient experiences per year while on treatment. It is the primary endpoint regulators have long accepted for relapsing MS because relapses can be counted and independently adjudicated. A significant reduction in ARR is generally required to secure an MS label.
Why is safety the key issue for BTK inhibitors in MS?
Several BTK inhibitors developed for multiple sclerosis have run into liver toxicity, including elevated liver enzymes and cases of drug-induced liver injury. Those findings have led to dose holds, trial pauses and restrictive monitoring requirements. Because MS patients take therapy for decades, tolerability problems undercut the main advantage of an oral drug over infused antibodies.
How could an MS indication help Novartis commercially?
Multiple sclerosis is a large, high-value specialty market, and Novartis already sells MS therapies, so it has neurology sales infrastructure and payer relationships in place. Adding an indication to an already approved pill avoids new manufacturing and commercial buildout, though a successful Rhapsido launch could cannibalize some of Novartis' existing MS revenue.
How did Novartis shares perform most recently?
Novartis (NVS) last closed at 152.06, down 1.14% from a prior close of 153.81, with a session range of 151.69 to 152.74, as of the final trade on Aug. 31, 2026 at 20:00 GMT. The wider market was mixed that day: SPY closed at $767.05, DIA at $531.57 and QQQ at $716.76.
Sources
Photo: Tima Miroshnichenko · Pexels Licence — source
